Cargando…

NI-05 CLINICOPATHOLOGICAL ANALYSIS AND METHIONINE PET ANALYSIS IN PATIENTS WITH GLIOMATOSIS CEREBRI

OBJECTIVE: Gliomatosis cerebri (GC) was defined as the tumor infiltrating into more than three lobes in WHO2007, but was deleted in WHO2016 because they include genetically heterogeneous tissues. However, we often encounter the cases with strongly invasive glioma. Then, we clinically analyzed the ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Yano, Hirohito, Nakayama, Noriyuki, Ohe, Naoyuki, Miyai, Masafumi, Yamada, Tetsuya, Miwa, Kazuhiro, Shinoda, Jun, Iwama, Toru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213396/
http://dx.doi.org/10.1093/noajnl/vdz039.118
_version_ 1783531794537119744
author Yano, Hirohito
Nakayama, Noriyuki
Ohe, Naoyuki
Miyai, Masafumi
Yamada, Tetsuya
Miwa, Kazuhiro
Shinoda, Jun
Iwama, Toru
author_facet Yano, Hirohito
Nakayama, Noriyuki
Ohe, Naoyuki
Miyai, Masafumi
Yamada, Tetsuya
Miwa, Kazuhiro
Shinoda, Jun
Iwama, Toru
author_sort Yano, Hirohito
collection PubMed
description OBJECTIVE: Gliomatosis cerebri (GC) was defined as the tumor infiltrating into more than three lobes in WHO2007, but was deleted in WHO2016 because they include genetically heterogeneous tissues. However, we often encounter the cases with strongly invasive glioma. Then, we clinically analyzed the cases of GC. PATIENTS AND METHODS: Seven cases (five men, median age: 57 years (23-89y)) diagnosed as GC in our hospital were included. Data of methionine-positron emission tomography (Met-PET), IDH and p53 mutation, MIB1-labeling index (LI) by immunohistochemistry were searched. We compared the accumulation areas of the Met-PET with the hyperintensity area (T2/FLAIR-high) and gadolinium-enhanced area on the MRI. We also examined a biopsy method, sites and a treatment regimen and analyzed overall survival (OS) and progression-free survival (PFS). RESULTS: The primary symptoms were disorientation in five, epileptic seizure and abnormal vision were two, respectively. The largest lesion area with the image was T2/FLAIR-high, followed by Met-PET and Gd in all. The surgical methods were stereotactic biopsy (2), navigation-guided biopsy (2), endoscopic biopsy (1), and craniotomy (2), The average of tumor/normal ratio in Met-PET was 2.92 (1.97–5.0). The pathological grade was diagnosed as Grade III in 4 and Grade II in 3. IDH1R132H was negative in all, p53 was positive in 5, and an average of MIB-1LI was 12% (2–35). The radiotherapy was performed in 6 cases, and, temozolomide was given to all, and bevacizumab was in 3. Six patients died of a tumor. Median PFS and OS were 8mos and 16.5mos, respectively. CONCLUSION: Because the GC cannot expect improvement by surgery, it is necessary to obtain the pathological diagnosis by a quick and correct biopsy, and the neurologic deterioration by the biopsy technique should be avoided. The Met-PET suggesting the highest grade site was useful for the plan of the biopsy site.
format Online
Article
Text
id pubmed-7213396
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-72133962020-07-07 NI-05 CLINICOPATHOLOGICAL ANALYSIS AND METHIONINE PET ANALYSIS IN PATIENTS WITH GLIOMATOSIS CEREBRI Yano, Hirohito Nakayama, Noriyuki Ohe, Naoyuki Miyai, Masafumi Yamada, Tetsuya Miwa, Kazuhiro Shinoda, Jun Iwama, Toru Neurooncol Adv Abstracts OBJECTIVE: Gliomatosis cerebri (GC) was defined as the tumor infiltrating into more than three lobes in WHO2007, but was deleted in WHO2016 because they include genetically heterogeneous tissues. However, we often encounter the cases with strongly invasive glioma. Then, we clinically analyzed the cases of GC. PATIENTS AND METHODS: Seven cases (five men, median age: 57 years (23-89y)) diagnosed as GC in our hospital were included. Data of methionine-positron emission tomography (Met-PET), IDH and p53 mutation, MIB1-labeling index (LI) by immunohistochemistry were searched. We compared the accumulation areas of the Met-PET with the hyperintensity area (T2/FLAIR-high) and gadolinium-enhanced area on the MRI. We also examined a biopsy method, sites and a treatment regimen and analyzed overall survival (OS) and progression-free survival (PFS). RESULTS: The primary symptoms were disorientation in five, epileptic seizure and abnormal vision were two, respectively. The largest lesion area with the image was T2/FLAIR-high, followed by Met-PET and Gd in all. The surgical methods were stereotactic biopsy (2), navigation-guided biopsy (2), endoscopic biopsy (1), and craniotomy (2), The average of tumor/normal ratio in Met-PET was 2.92 (1.97–5.0). The pathological grade was diagnosed as Grade III in 4 and Grade II in 3. IDH1R132H was negative in all, p53 was positive in 5, and an average of MIB-1LI was 12% (2–35). The radiotherapy was performed in 6 cases, and, temozolomide was given to all, and bevacizumab was in 3. Six patients died of a tumor. Median PFS and OS were 8mos and 16.5mos, respectively. CONCLUSION: Because the GC cannot expect improvement by surgery, it is necessary to obtain the pathological diagnosis by a quick and correct biopsy, and the neurologic deterioration by the biopsy technique should be avoided. The Met-PET suggesting the highest grade site was useful for the plan of the biopsy site. Oxford University Press 2019-12-16 /pmc/articles/PMC7213396/ http://dx.doi.org/10.1093/noajnl/vdz039.118 Text en © The Author(s) 2019. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Yano, Hirohito
Nakayama, Noriyuki
Ohe, Naoyuki
Miyai, Masafumi
Yamada, Tetsuya
Miwa, Kazuhiro
Shinoda, Jun
Iwama, Toru
NI-05 CLINICOPATHOLOGICAL ANALYSIS AND METHIONINE PET ANALYSIS IN PATIENTS WITH GLIOMATOSIS CEREBRI
title NI-05 CLINICOPATHOLOGICAL ANALYSIS AND METHIONINE PET ANALYSIS IN PATIENTS WITH GLIOMATOSIS CEREBRI
title_full NI-05 CLINICOPATHOLOGICAL ANALYSIS AND METHIONINE PET ANALYSIS IN PATIENTS WITH GLIOMATOSIS CEREBRI
title_fullStr NI-05 CLINICOPATHOLOGICAL ANALYSIS AND METHIONINE PET ANALYSIS IN PATIENTS WITH GLIOMATOSIS CEREBRI
title_full_unstemmed NI-05 CLINICOPATHOLOGICAL ANALYSIS AND METHIONINE PET ANALYSIS IN PATIENTS WITH GLIOMATOSIS CEREBRI
title_short NI-05 CLINICOPATHOLOGICAL ANALYSIS AND METHIONINE PET ANALYSIS IN PATIENTS WITH GLIOMATOSIS CEREBRI
title_sort ni-05 clinicopathological analysis and methionine pet analysis in patients with gliomatosis cerebri
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7213396/
http://dx.doi.org/10.1093/noajnl/vdz039.118
work_keys_str_mv AT yanohirohito ni05clinicopathologicalanalysisandmethioninepetanalysisinpatientswithgliomatosiscerebri
AT nakayamanoriyuki ni05clinicopathologicalanalysisandmethioninepetanalysisinpatientswithgliomatosiscerebri
AT ohenaoyuki ni05clinicopathologicalanalysisandmethioninepetanalysisinpatientswithgliomatosiscerebri
AT miyaimasafumi ni05clinicopathologicalanalysisandmethioninepetanalysisinpatientswithgliomatosiscerebri
AT yamadatetsuya ni05clinicopathologicalanalysisandmethioninepetanalysisinpatientswithgliomatosiscerebri
AT miwakazuhiro ni05clinicopathologicalanalysisandmethioninepetanalysisinpatientswithgliomatosiscerebri
AT shinodajun ni05clinicopathologicalanalysisandmethioninepetanalysisinpatientswithgliomatosiscerebri
AT iwamatoru ni05clinicopathologicalanalysisandmethioninepetanalysisinpatientswithgliomatosiscerebri